Background: Physical activity (PA) improves fatigue and quality of life (QOL) in cancer survivors. Our aim was to assess whether a 2-month PA intervention improves fatigue and QOL for people with advanced lung cancer.
Introduction
Lung cancer remains the commonest cause of cancer death worldwide. The 5-year survival rate in Australia is 14%, with most diagnosed with advanced disease, and a median survival of 9-12 months. Patients with lung cancer have high symptom burden, with fatigue and poor quality of life (QOL) [1] .
Meta-analyses have shown physical activity (PA) can improve outcomes in cancer survivors, improving fitness and QOL [2, 3] . Observational studies suggest PA can decrease the risk of some cancers, and may reduce recurrence, and improve cancer specific and all cause mortality [3, 4] .
Evidence for benefits of PA in advanced cancer is limited, with few studies evaluating PA in people with lung cancer. One study found only 27% of lung cancer patients met PA guidelines [5] . Those who exercised had better QOL.
We aimed to evaluate the effect of a structured, individualized, 8-week PA intervention on fatigue and QOL in people with advanced lung cancer. Primary hypothesis was that the PA intervention would improve fatigue and QOL.
Methods and patients
This was a two arm, open-label, randomized controlled trial (RCT) comparing an 8-week individualized PA programme (experimental arm: EX) to usual care (UC) in ambulatory patients with advanced lung cancer ( Figure 1 ; supplementary Figure S1 , available at Annals of Oncology online) recruited from five Sydney hospitals [6] . Each institution provided Ethics approval and all participants gave written informed consent.
Eligibility criteria included: histological diagnosis of non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC), with stage III/IV disease (stage III NSCLC or limited stage SCLC must have completed chemo-radiotherapy !4 weeks prior, with an incomplete response; stage IV patients could be receiving anti-cancer treatment); an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2; life expectancy >6 months; sufficient English to complete questionnaires; and assessed medically fit by treating physician and Physical Activity Readiness Questionnaire (PAR-Q) [7] . Initially, participants meeting recommended guidelines of !10 metabolic equivalent of task (MET) h/ week were excluded. In 2011, this exclusion was removed as patients often deteriorated quickly once PA began to decline.
Patients were randomized (1:1) via central Interactive Voice Response System, with stratification by disease stage (locally advanced versus metastatic), PS (0-1 versus 2), and centre. Treatment allocation was determined by minimization. Allocation was not blinded due to nature of the intervention.
The intervention is described elsewhere [6] . Briefly, all participants received cancer-specific exercise (Move Your Body) and nutrition (Eat For Health) education materials. Patients randomized to UC attended study assessments only. Participants randomized to EX had eight weekly sessions with an exercise provider. Exercise was individualized to baseline fitness and interests. It included a behaviour change programme based on Theory of Planned Behaviour [8] . The goal was to increase recreational PA by >3 MET h/ week. Sessions lasted $1 h: $45-min PA; $15-min behaviour support. PA was predominantly aerobic, and home-based PA was encouraged. EX participants received a pedometer, PA diary, and workbook.
Outcomes were assessed at baseline, 2, 4 and 6 months ( Figure 1 ) when participants completed patient-reported outcomes (PRO), fitness test and gave blood. The week before assessments participants wore an accelerometer [9] (ActiGraph, LLC, Fort Walton Beach, FL) to measure PA. Disease and treatment status was recorded, and survival to July 2016 determined from medical records.
Fatigue (primary outcome) was measured by 13-item Functional Assessment of Cancer Therapy-Fatigue (FACT-F) subscale [10] . Primary endpoint was difference in mean fatigue scores between groups at 2 months. Secondary outcomes included: QOL (European Organization for Research and Treatment of Cancer-QOL-Core (EORTC-QLQ-C30) and Lung module (LC-13 subscale) [11] ; activities of daily living (ADL) and instrumental activities of daily living (iADL) [12] ; anxiety and depression (General Health Questionnaire-12) [13] ; distress (Distress Thermometer) [14] ; cognitive symptoms (FACT-Cognition) [15] ; sleep quality (Pittsburgh Sleep Quality Index) [16] and dyspnoea (Shortness of Breath Questionnaire) [17] . Physical function, activity and fitness were measured by: 6-MWT [18] ; Senior's fitness test [18] ; hand grip strength; Actigraph GT1M accelerometers; Active Australia questionnaire [19] and Sedentary Behavior Questionnaire [20] . Details on calculation of objective and self-report PA are included in supplementary Appendix S1, available at Annals of Oncology online. Social Cognitive Determinants of Exercise questionnaire determined attitudes to PA. Pulmonary function was evaluated by spirometry with forced expiratory volume in 1-second (FEV1) and forced vital capacity (FVC). Anthropometric measurements, ECOG PS, co-morbidities and admissions were recorded. Blood samples for modified Glasgow Prognostic Score (C-reactive protein, albumin), cytokine levels and insulin-like growth factors (IGF) were collected. Adverse events were categorized using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)v3.
Statistical analysis
Sample size was calculated to detect a standardized effect size of 0.67 in fatigue between groups at 2 months [i.e. difference of six-points in mean FACT-F subscale score (range 0-52), assuming SD 9) [21] . A sample of 106 patients provided 80% power (two-tailed a 0.05, allowing 30% attrition).
Intention-to-treat analyses using linear mixed models to account for covariance between repeated measures were performed. We used unadjusted and pre-specified adjusted models [6] . Adjusted models included sex, age, disease stage and baseline outcomes. Fatigue was defined as FACT-F score 43/52 [22] .
Patterns of missing data were assessed and baseline characteristics of patients lost to follow-up compared with completers. Sensitivity analyses were performed using multiple imputation, including auxiliary data and baseline secondary.
Exploratory analysis of overall survival (OS), time from randomization to death, used the Kaplan-Meier method. Patients alive at final analysis, and those lost to follow-up, were censored at last contact date. Stratified log-rank test adjusting for stratification factors was performed. An exploratory per protocol analysis was performed comparing those who increased PA versus those who did not. Analyses were performed in SAS Version 9.4 (SAS Institute, Cary, NC).
Results
A total of 112 patients were recruited July 2009 to October 2014; 56 assigned to each group. One UC patient was ineligible and withdrawn. Participants included in each assessment and reasons for attrition are outlined in Figure 1 and supplementary Table S4 , available at Annals of Oncology online. Intervention adherence was good, with 69% completing all PA and 75% all behavioural change sessions. Disease progression was the main reason for attrition.
Median age was 64 years (range 34-80); 61 (55%) were male (Table 1) . Most had metastatic NSCLC (N ¼ 101, 95%), and PS 0-1 (N ¼ 107, 96%). Median time from diagnosis to randomization was 7.7 months UC and 8.6 months EX. Most (N ¼ 87, 78%) were receiving anti-cancer treatment (79% EX, 78% UC).
Groups were similar at baseline. Fatigue was high in both, with a mean score of 37.5 and 36.4 at 2 months for EX and UC, respectively. Fatigue was not significantly different between groups at 2 months (1.2, 95% CI À3.5, 5.8, P ¼ 0.62), or later (Table 2) . There was no difference in mean scores between groups at any time point in: QOL, lung symptoms (except sore mouth at 4 months), dyspnoea, stress, anxiety/depression, cognitive symptoms, sleep quality, ADL or iADL (Table 2) . Adjusted results were similar other than: distress and sore mouth at 4 months, and ADLs at 6 months, were better in EX (supplementary Table S1 , available at Annals of Oncology online).
Unadjusted mean self-reported PA levels were not different between groups at 2 months (EX 49.0 min/day versus UC 40.4 min/ day; P ¼ 0.38), the EX group had higher PA levels at 4 months (52.7 versus 31.1 min/day; P ¼ 0.039) and 6 month (51.4 versus 27.7 min/day; P ¼ 0.029) ( Table 3) . Adjusted results were similar (supplementary Table S2 , available at Annals of Oncology online). Change in self-reported PA ranged from À24.8 to 31.3 MET/h/ week in UC, and À21.9 to 66.8 in EX. Participants with complete data who increased PA by 3 MET/h/week from baseline to 2 months were UC 11/30 (37%) and EX 16/41 (39%).
Accelerometer data for moderate to vigorous-intensity PA showed less PA in both groups than self-report (Figure 2) . The unadjusted mixed model analysis of accelerometer data, using participants with !4 days data (N ¼ 94) showed EX increased mean duration of PA between baseline and 2 months, from 13.2 to 18.1 min/day, while UC reduced PA from 15.6 to 13.2 min/ day. Unadjusted differences between groups at 2 months were not significantly different, although the adjusted difference was: EX 7.1 min/day higher (95% CI: 0.6, 13.5; P ¼ 0.03).
Physical function, fitness and anthropometric measures were not different between groups at any time point (Table 3) .
There were no serious adverse events. Four EX patients had musculoskeletal events likely related to exercise (back or muscle soreness) resolving without treatment. Another four EX patients had minor adverse events, which resolved without intervention. There were no differences in number of hospital admissions or length of stay, with 69 admissions, averaging 7 days/admission. Correlative biological studies found no difference between groups at any assessment on Glasgow Prognostic Score, haemoglobin, neutrophil: lymphocyte or IGF. C-reactive protein was higher at 2 months in EX (supplementary Table S3 , available at Annals of Oncology online). Some liver function test results at 4 and 6 months were higher in EX, but were not clinically important. Cytokine samples are stored, pending funding for analysis.
Exploratory analysis
We compared participants who increased self-reported PA from baseline to 2 months, and whose self-reported PA stayed the same or decreased. Fatigue decreased among 38 (22 EX) who increased PA, and increased in 73 (34 EX) who did not. Difference in change in fatigue was À4.7 (95% CI: À8.5, À0.9; P ¼ 0.015). A similar result was found using accelerometer-measured PA (À4.0, 95% CI: À7.8, À0.2; P ¼ 0.04).
A comparison of baseline data for primary outcome between those with complete versus incomplete data, showed those with incomplete data were more ill, with poorer PS, more comorbidities, poorer QOL, worse ADL function and shorter survival (supplementary Table S5A -C, available at Annals of Oncology online). There were no significant differences in baseline PA and fitness measures (supplementary Table S5D , available at Annals of Oncology online).
A sensitivity analysis using multiple imputation found similar results for fatigue, and no significant differences for accelerometer data within or between groups (supplementary  Appendix S3 and Tables S6 and S7 , available at Annals of Oncology online).
Discussion
Our study confirms people with advanced lung cancer can participate in a structured PA programme, but we found no differences to support our primary hypothesis that PA would improve fatigue and QOL. Two other RCTs of PA in lung cancer populations are published [23, 24] . One randomized 116 lung cancer patients (65% stage I) to a 12-week, home-based walking programme (40 min/3 days weekly) with exercise counselling or UC. The exercise group's anxiety and depression improved. Adherence was low: 45% assigned to PA completed the intervention, and adherence to exercise was 60%. The other RCT, in advanced lung cancer, randomized 46 patients receiving in-patient chemotherapy to conventional physiotherapy versus specialized physiotherapy with strength and endurance training. Only 29 patients completed the trial. After the third chemotherapy cycle the intervention group had significantly better scores on the Bartel Index (primary endpoint), and a range of secondary endpoints. Results are promising but should be viewed cautiously due to small sample size, and significant baseline differences between groups in endurance and strength.
Courneya found similar results to ours in colorectal cancer survivors randomized to home-based PA or wait-list UC. They reported exercise contamination, with no difference in PA or QOL between groups. Post hoc analysis revealed QOL and anxiety differences in those who increased fitness compared with those who did not [25] . We also found minimal differences in PA between groups, possibly explaining the lack of difference in outcomes. Contamination between groups is plausible, or the PA intervention being insufficiently intensive.
At baseline our groups reported more PA than expected. EX self-reported higher PA levels compared with UC at 4 (53 versus 31 min/day) and 6 months (51 versus 28 min/day), but not 2 months. Asking this population whether PA made them breathe harder may have resulted in overestimation of vigorous activities, weighted higher in MET-hours conversion.
Accelerometer data showed higher rates of moderate-vigorous PA in EX compared with UC, with significant longitudinal increases in EX, while UC showed non-significant decline. This suggests EX achieved higher intensity of PA than UC, but a more intensive PA programme might be required to improve fatigue and QOL.
Higher self-reported PA compared to accelerometer data has been reported previously [26] , highlighting the importance of objective measurement. Reasons for the discrepancy may include: (i) accelerometers focus on moderate-vigorous PA, whereas questionnaires record all PA; (ii) accelerometers are suboptimal for detecting some activities (e.g. cycling); (iii) number of participants with 4þ days of accelerometer data was less than those completing questionnaires; those without valid accelerometer data may have been less active, and (iv) participants may select socially desirable responses.
Both groups doubled the mean distance in 6-MWT from baseline to 2 months ($243 to 517 min), maintained at 4 and 6 months. Improvements of 30 m are clinically important in populations with chronic obstructive pulmonary disease [27] .
Despite our population, intervention adherence was good (attendance: PA 69%, behavioural 75%). Other studies report 60%-70% PA attendance rates in early-stage cancer populations [28] . Attrition was equal between groups; the sickest patients dropped out early, and patients with better function and fewer symptoms remained.
There was no difference between groups in proportion of patients receiving anti-cancer treatment; therefore any effect of active treatment on fatigue or QOL could be expected to be the same. Our exploratory analysis showed those increasing PA above baseline had significant improvements in fatigue, suggesting PA maybe beneficial. However, causal mechanisms cannot be assumed as randomization has been disregarded: participants with fewer symptoms and better PS may have been well enough to increase PA. 
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Limitations Participants' baseline characteristics are atypical of advanced lung cancer patients (with median 8 months from diagnosis) making findings difficult to generalize. Both groups reported more baseline PA than anticipated, and symptoms and physical function did not deteriorate greatly over time. Our results suggest self-selection bias in those consenting to participate. Willingness to participate in a PA study, education materials and fitness assessments may encourage all to do more PA, leading to contamination. As expected, attrition occurred throughout the study.
Although not significant, it was greater in UC; which could lead to bias. Finally, an open-label intervention has the potential to influence patient reported outcome responses.
Conclusions
People with advanced lung cancer are able to participate in structured PA programmes. Our intervention did not improve fatigue and QOL in an advanced lung cancer population. The intervention may not have been intensive enough to produce a difference in PA between groups, the population may not represent most advanced lung cancer patients, and contamination may have occurred in UC. We recommend a RCT evaluating a more intensive PA in patients closer to diagnosis, while better controlling for contamination, to determine if a structured PA intervention can improve fatigue in such patients.
